KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: Clues for its potential use in second-line therapy decision making

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 1, 2015, Pages 33-40

  Campos Parra, Alma D ^a   Zuloaga, Carlos ^b   Manríquez, María Eugenia Vazquez ^b   Avilés, Alejandro ^c   Borbolla Escoboza, Jose ^d   Cardona, Andrés ^e   Meneses, Abelardo ^a   Arrieta, Oscar ^a,b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^c Department of Pathology ^*  (Mexico)

^d Boehringer Ingelheim   (Mexico)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

Author keywords

chemotherapy; EGFR; EGFR tyrosine kinase inhibitors; genotyping NSCLC; KRAS; Lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ERLOTINIB; GEFITINIB; K RAS PROTEIN; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DRUG USE; ELECTROCORTICOGRAPHY; EXON; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

EID: 84964264802     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318287bb23     Document Type: Article

References (25)

1. Burdett S. Chemotherapy in addition to supportive care improves survival advanced non-small-cell lung cancer: a systematic review and meta-Analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617-4625.
2. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage nonsmall-cell lung cancer. J Clin Oncol. 2008;20:3543-3551.
3. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-1597.
4. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306-13311.
5. Shih J, Yang C, Su W, et al. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). J Clin Oncol. 2010;28:15s, (suppl; abstr 7521
6. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012;13:539-548.
7. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735-742.
8. Arrieta O, Cardona AF, Federico Bramuglia G, et al. Genotyping non-small cell lung cancer (NSCLC) in Latin-America. J Thorac Oncol. 2011;6:1955-1959.
9. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866-2874.
10. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e17.
11. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900-5909.
12. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and ras for adjuvant chemotherapy in non-small-cell lung cancer. J Clin Oncol. 2007;25: 5240-5247.
13. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers a different disease. Nat Rev Cancer. 2007;7:778-790.
14. Azzoli CG, Temin S, Aliff T, et al. Focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2011;29:3825-3831.
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
16. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-144.
17. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13:300-308.
18. Krawczyk P, Kowalski DM, Wojas-Krawczyk K, et al. The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors. Chemotherapy. 2012;58:60-69.
19. Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol. 2010;75:173-234.
20. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-Analysis. Br J Cancer. 2004; 92:131-139.
21. Rosell R, González-Larriba JL, Alberola V, et al. Single-Agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity. Semin Oncol. 1995;22(6 suppl 14):12-18.
22. Scoccianti C, Vesin A, Martel G, et al. Prognostic value of TP53, KRAS and EGFR mutations in non-small cell lung cancer: EUELC cohort. Eur Respir J. 2012;40:177-184.
23. Kalikaki A, Koutsopoulos A, Hatzidaki D, et al. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung cancer. 2010;69:110-115.
24. Mak RH, Doran E, Muzikansky A, et al. Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist. 2011;16:886-895.
25. Arrieta O, Campos-Parra AD, Zuloaga C, et al. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small cell lung cancer related to wood-smoke exposure. J Thorac Oncol. 2012;7:1228-1234.